Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06866964 · ClinicalTrials.gov registry record · Phase 2
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
A Phase 2 study of Germ Cell Tumor and Testicular Cancer, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 3
- Study locations
NCT06866964: Recruiting Phase 2 study of Germ Cell Tumor and Testicular Cancer, sponsored by Wake Forest University Health Sciences.
NCT06866964 is a Phase 2 study of Germ Cell Tumor and Testicular Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 35 participants, below the 346-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06866964, a Phase 2 study of Germ Cell Tumor and Testicular Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
Primary Outcome
A binary variable indicating whether the participant had zero VTE events within 26 weeks of initiation of standard chemotherapy. VTE events include objectively confirmed symptomatic or asymptomatic proximal deep-vein thrombosis in a lower limb, symptomatic deep-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, symptomatic or incidental pulmonary embolism, symptomatic or incidental central catheter related thrombosis, or death from venous thromboembolism.
Conditions Studied
Interventions
- DRUG Low-dose ASA
Study Locations (3)
North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Charlotte
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Wisconsin
- Aurora St. Luke's Medical Center MOB - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2031-01 |
| Phase | Phase 2 |
What NCT06866964 shows while recruiting
NCT06866964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 346-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Low-dose ASA is the first listed.
NCT06866964 reports a single indexed study location in North Carolina, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06866964 about?
NCT06866964 is a clinical study titled "A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy". The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
What is the current status of trial NCT06866964?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-08-28. Estimated completion is 2031-01.
What conditions does trial NCT06866964 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Testicular Cancer.
What interventions are being tested in trial NCT06866964?
The interventions under investigation include: Low-dose ASA (DRUG).
Who is sponsoring clinical trial NCT06866964?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06866964 being conducted?
This trial has 3 study locations across North Carolina, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06866964's enrollment target sits among peer trials
35 15th of 19 higher than 5 of 19 other Germ Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
ACTIVE NOT RECRUITING · Phase 2
-
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI